Avatrombopag (Doptelet)
Revision as of 00:10, 20 July 2018 by Warner-admin (talk | contribs) (Text replacement - "Category:Autoimmune thrombocytopenic purpura" to "Category:Immune thrombocytopenia")
Mechanism of action
Thrombopoietin receptor agonist
Diseases for which it is used
- Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. link to original article PubMed
History of changes in FDA indication
- 5/21/2018: FDA approved "for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure."
Also known as
- Code names: E5501, YM477, AKR 501
- Brand name: Doptelet